Excellent
Patient Risk:
Low
Summary
The AI-generated claim matches WEGOVY labeling regarding rodent thyroid C-cell tumor findings, human relevance being unknown, the contraindication in patients with personal/family history of MTC or MEN 2, counseling on symptoms, and the labeled statement that routine calcitonin/thyroid ultrasound monitoring is of uncertain value.
Category Scores
Accurate Statements
In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors; human relevance is unknown.
WEGOVY SECTION 5.1 — Risk of Thyroid C-Cell Tumors; supported by SECTION 13.1 (carcinogenesis findings in mice/rats and unknown human relevance).
WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
WEGOVY SECTION 4 — Contraindications; reiterated in SECTION 5.1.
Counsel patients about symptoms of thyroid tumors.
WEGOVY SECTION 5.1 — Counsel patients regarding potential risk for MTC and inform them of symptoms (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring with calcitonin and/or thyroid ultrasound is of uncertain value for early detection.
WEGOVY SECTION 5.1 — “Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC…”
Unsupported Statements
Contradictions
Important Omissions
The claim does not include the label’s additional details that: (1) cases of MTC in patients treated with liraglutide have been reported, and the data are insufficient to establish or exclude causality; and (2) if calcitonin is measured and elevated, further evaluation is recommended and patients with thyroid nodules should be evaluated.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claim accurately reflects the core contraindication, nonclinical risk statement, and the label’s monitoring/counseling position; omissions are limited to additional evaluative guidance and contextual postmarketing/threshold details that are not required for the specific claim as written.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Primary Issue
Suggested Improvement
To be even closer to the label, optionally include that monitoring is of uncertain value and that significantly elevated calcitonin may warrant further evaluation, and note the liraglutide postmarketing context mentioned in SECTION 5.1.